INTRODUCTION
Histamine (HA) exhibits its biological effects through the activation of four different G protein-coupled receptors (GPCRs). The histamine H 1 -receptor (H 1 R) is associated with inflammatory and allergic reactions, e. g. it increases vascular permeability and NO production [1] . The histamine H 2 -receptor (H 2 R) regulates gastric acid production, but also shows a positive inotropic effect on the heart [1] . The histamine H 3 -receptor (H 3 R) is a presynaptic auto-and heteroreceptor, regulating the release of HA and various other neurotransmitters in the nervous system, and is involved in important physiological processes like the sleep-wake cycle, eating behaviour and cognition [2] . The histamine H 4 -receptor (H 4 R) mediates inflammatory and immunological processes, e. g. chemotaxis of eosinophils, mast cells and dendritic cells, but it is also present on neurons mediating HAinduced itching [3, 4] . H 1 R and H 2 R antagonists have been used as therapeutics for decades, H 3 R and H 4 R are still explored and promising new drug targets [5] .
The H 3 R was pharmacologically identified in the early 1980s, but cloned almost 20 years later in 1999 as an orphan GPCR [2] . The reason for this delay was that it only shares ~20% homology to the H 1 R and H 2 R. The complex gene structure of the human H 3 R (hH 3 R) gives rise to many possible splice variants. To date about 20 hH 3 R splice variants are known [6] , but their function still remains elusive. The H 3 R displays high constitutive, i. e. ligandindependent, activity in many experimental systems [7] . The H 3 R is one of the very few GPCRs for which constitutive activity has also been demonstrated in vivo [8] .
For the H 3 R it has also been shown that species-differences exist [9, 10] . Fig. 1 shows the amino acid sequences of hH 3 R and rH 3 R. Although the H 3 R sequence has a high degree of similarity among species, differences located in key regions of the receptor protein account for differences in antagonist affinity [13, 14] . Additionally, splice variants differ in composition and expression pattern between species, and there are potential differences in signal transduction processes between either tissues and/or species [15] . Nevertheless, there are still unresolved questions about species differences of the full-length and un-
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In the present study, we systematically compared the pharmacological properties of hH 3 R and rH 3 R. Fig. 2 shows the structures of the compounds studied, all of them being imidazole-containing ligands. We co-expressed hH 3 R and rH 3 Many studies of ligand-receptor interactions come to a point where structural information on the atomic level is needed to explain experimental results. In the case of GPCRs, this is a very challenging and time-consuming process, and at the end only snapshots of static ligand-receptor complexes are resolved [16] . However, more and more high-resolution crystal structures of inactive-and active-state GPCR-ligand complexes are becoming available and can be used to generate better homology models [17, 18, 19] .
Several molecular modelling studies with regard to ligand-receptor interaction at H 3 R are found in literature [13, 20, 21, 22] . Since active-state models for H 3 Rs do not yet exist, we generated and used those models to explain the pharmacological species differences at hH 3 R and rH 3 R on the basis of experimental data.
5

MATERIALS AND METHODS
Materials.
The cDNAs of the hH 3 R and rH 3 R were kindly provided by Dr. T. Lovenberg (Johnson & Johnson Pharmaceutical R&D, San Diego, CA, USA). An alignment of the corresponding amino acid sequences is given in Fig. 1 . Anti-hH 3 R Ig and anti-rH 3 R Ig were from Bio-Trend (Cologne, Germany). The antibody recognizing both species homologs was from GeneWay (San Diego, CA, USA). All other antibodies, purified G proteins, reagents for molecular biology, recombinant baculoviruses encoding mammalian G protein subunits, and the sources of test compounds were described before [23] . Chemical structures of H 3 R ligands are depicted in Fig. 2 . Stock solutions (10 mM) of all H 3 R ligands described in this paper were prepared in distilled water and stored at -20°C. was synthesized as described [23] . Unlabeled nucleotides were from Roche (Indianapolis, IN, USA) and all other reagents were of the highest purity available and from standard suppliers.
Construction of FLAG epitope-and hexahistidine-tagged cDNAs for hH 3 R and rH 3 R.
The cDNA for the tagged rH 3 R protein was generated by sequential overlap-extension PCR in analogy to the procedure described recently for hH 3 R [23] . In the case of rH 3 R, the sense primer RAT HRH3-F-(5´-GAC GAT GAT GAC GCC ATG GAG CGC GCG CCG CC-3´) consisted of 15 bp of the 3'-end of SF and the first 17 bp of the 5'-end of the rH 3 R. The antisense primer RAT HRH3-RV (5´-GA TCC TCT AGA TTA GTG ATG GTG ATG ATG GTG CTT CCA GCA CTG CTC -3´) consisted of 15 bp of the C-terminus of the rH 3 R, and encoded a hexahistidine tag, the stop codon, and a Xba I site. As template, a plasmid (pCIneo) containing the sequence of rH 3 R was used.
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SDS-PAGE and immunoblot analysis.
The protocols for virus amplification, protein expression and western blot analysis were described before [23] . Proteins transferred to nitrocellulose membranes were reacted with anti-hH 3 R (N-term) (1:1000), anti-rH 3 R (C-term) (1:1000) and anti-H 3 R (i3) (1:1000) Igs.
[
S]GTPS saturation binding assay.
Experiments were performed in analogy to the assay described in Schnell et al. [23] .
Membranes were thawed and sedimented by a 10-min centrifugation at 4°C and 15,000g to remove residual endogenous guanine nucleotides as far as possible. Membranes were S]GTPγS by filtration through GF/C filters, followed by three washes with 2 ml of binding buffer (4°C). Filter-bound radioactivity was determined by liquid scintillation counting.
The experimental conditions chosen ensured that not more than 10 % of the total amount of radioactivity added to binding tubes was bound to filters. The maximum number of Gα i/orelated GTPγS binding sites in membranes expressing H 3 Rs plus Gα-subunits plus β 1 γ 2 was corrected by the binding determined in parallel in membranes expressing H 3 Rs plus β 1 γ 2 alone. These reference membranes were always prepared under exactly the same conditions as the other ones. To ensure the same viral load in the reference membranes, Sf9 cells were infected with baculoviruses encoding H 3 Rs, β 1 γ 2 and virus encoding no recombinant protein at all. In this manner, only the number of functionally intact and heterologously expressed mammalian Gα i/o -subunits was quantitated. Experiments were performed in analogy to the assay described in Schnell et al. [23] . Briefly, membranes were thawed, sedimented and resuspended in 10 mM Tris/HCl, pH 7. 
Radioligand binding assays.
Membranes were thawed and sedimented by a 10-min centrifugation at 4°C and 15,000g and resuspended in binding buffer (12.5 Filter-bound radioactivity was determined by liquid scintillation counting. The experimental conditions chosen ensured that not more than 10 % of the total amount of radioactivity added to binding tubes was bound to filters.
Construction of inactive and active models of hH 3 R and rH 3 R.
Based on the crystal structure of the human β 2 -adrenergic receptor [17, 24] , a homology model of the inactive hH 3 R and rH 3 R were generated. Based on the active state model of guinea pig H 1 R (gpH 1 R) [25, 26] , an active model of hH 3 R was constructed by homology modelling. All models were refined and energetically minimized with SYBYL 7.0 (Tripos, St.
Louis, MO, USA), as described [27] . Imoproxifan was docked manually into the binding pocket of the active hH 3 R and the inactive rH 3 R. Thereby, previous results of similar compounds were taken into account [20, 21] . The resulting structures were embedded in a simulation box, including lipid bilayer, water, sodium and chlorine ions, as described [28] .
Subsequently, molecular dynamic simulations with GROMACS 3.3.1 [29] were performed, using a simulation protocol, previously described [28] . 9 2.8. Miscellaneous.
Molecular biology was planned with GCK 2.5 (Textco BioSoftware, West Lebanon, NH, USA). Ligand structures were illustrated using ChemDraw Ultra 8.0 (CambridgeSoft, Cambridge, MA, USA). The sequence alignment was performed using ClustalX (2.0), which is a windows interface based on the Clustal W algorithm [30] . Protein was determined using the DC protein assay kit (Bio-Rad, Hercules, CA, USA). [ 3 H]Dihydroalprenolol was obtained from Perkin Elmer (Boston, MA, USA) and protein quantification via western blot performed as described in Schnell et al. [23] . All analyses of experimental data were performed with the Prism 5 program (GraphPad Software, San Diego, CA, USA).
RESULTS
Western blot analysis of hH 3 R and rH 3 R expressed in Sf9 insect cell membranes.
Membranes of Sf9 cells expressing hH 3 R or rH 3 R plus mammalian G proteins were prepared and analyzed via immunoblot. It has to be mentioned, that membranes co-expressing rH 3 R plus different mammalian G proteins were prepared in parallel and under exactly the same conditions as the membranes expressing hH 3 R [23] . Thus, the comparison of hH 3 R and rH 3 R pharmacology in this system is not based on historical data but direct. Both hH 3 R and rH 3 R bands were doublets, probably representing differently glycosylated forms (Fig. 3 ). H 3 R species homologs presumably exhibit similar glycosylation patterns since the putative Nglycosylation site for the H 3 R (Asn11) is fully conserved within their sequences (Fig. 1) . The H 3 R species homologs could be clearly discriminated by anti-hH 3 R Ig, raised against an 18 amino acid peptide within the extracellular N-terminus of the hH 3 R, and anti-rH 3 R Ig, raised against an 18 amino acid peptide within the cytoplasmatic C-terminus of the rH 3 R (Figs. 3A and 3B). Additionally, anti-H 3 R (i3) Ig was used to confirm the above mentioned results (Fig.   3C ). This antibody was raised against a peptide sequence within the third intracellular loop (i3) of the hH 3 R, but turned out to be not species-selective. Again, all H 3 R bands occurred as doublets at ~49 kDa. However, there were some additional bands at lower molecular weight, which are presumably non-specific, since they also appeared at the control lane loaded with
Page 10 of 42
A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 uninfected Sf9 cell membranes. Thus, our data indicate that hH 3 R and rH 3 R were equally well and properly expressed in Sf9 cells. In analogy to our recent publication [23] , the rH 3 R was also co-expressed with different mammalian G proteins (Gα i1 , Gα i2 , Gα i3 or Gα o1 , and β 1 γ 2 dimers, respectively) to analyze the coupling profile. All proteins were properly detected by different selective antibodies (Fig. 3) . Moreover, we also quantified the expression levels of receptors and G proteins by immunoblot, using hβ 2 AR or purified G protein subunits as standards ( Fig. 3D and 3H, I ). The results of these studies are summarized in Table 1 .
Quantitative analysis of receptor-to-G protein stoichiometries.
Protein quantification via western blot is semi-quantitative and does not discriminate between functional and non-functional proteins. Therefore, we directly used a recently described combination of antagonist [³H]JNJ-7753707-and [
35
S]GTPγS-saturation binding [23] and calculated the functional GPCR/Gα protein ratios (Table 1 ). Similar to the membranes expressing hH 3 R, we detected an excess of mammalian G proteins in the case of rH 3 R, confirming the previously reported results [23] . Thus, G protein expression level is not limiting in this experimental system, too.
hH 3 R and rH 3 R coupling to different Gα-subunits.
The G protein coupling profile of rH 3 R (Table 2) was also investigated as for the hH 3 R [23] .
Briefly, receptor-dependent [γ-32 P]GTP hydrolysis of different Gα-subunits was measured under steady-state conditions. GTPase activities were determined in parallel under basal conditions, maximal stimulation with the physiological (and full) agonist histamine (10 µM) and a saturating concentration of the inverse agonist thioperamide (10 µM) in Sf9 cell membranes co-expressing the rH 3 R and different G proteins.
Like hH 3 R, rH 3 R coupled efficiently to all co-expressed mammalian Gα i/o -subunits (Gα i1 , Gα i2 , Gα i3 or Gα o1 , and β 1 γ 2 dimers, respectively), as was evident by the high basal GTPase activities and the large absolute stimulatory and inhibitory effects of histamine and thioperamide, respectively (Table 2) . Also, the relative stimulatory effects of histamine and
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A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 the relative inhibitory effects of thioperamide based on total ligand-regulated GTPase activity were similar for each of the four systems studied, indicating that the constitutive activity of rH 3 R was comparable and not substantially influenced by the type of G protein ( Table 2 ). The constitutive activity of rH 3 R coupled to cognate G i /G o -proteins was rather high and comparable to the constitutive activity of hH 3 R, rendering the two systems suitable for an analysis of species-specific ligand effects, without possible bias due to differences in basal activity between membranes.
3.4. Ligand potencies and efficacies in the steady-state GTPase assay at rH 3 R compared to hH 3 R co-expressed with different Gα-subunits.
Next, we examined a series of imidazole-based ligands in Sf9 cell membranes expressing rH 3 R and different Gα i/o -proteins in the steady-state GTPase assay. The data (Table 3) were then compared with the results for hH 3 R [23] (Fig. 4 A and B) . The endogenous agonist histamine (1) and the standard H 3 R ligands N  -methylhistamine (2) and (R)--methylhistamine (3) were full agonists and equally potent in all membranes. There were essentially no species-differences. The highly potent standard H 3 R agonist imetit (4) was almost a full agonist at rH 3 R, too. Interestingly, proxifan (5) was again a strong partial agonist in all systems, independent of the G protein subtype co-expressed, corroborating the notion that this ligand does not show functional selectivity at H 3 Rs [23] . In contrast to hH 3 R, impentamine (6) was a strong and more potent partial agonist at rH 3 R in all experimental settings. Strikingly, imoproxifan (7) was an almost full agonist at hH 3 R (Fig. 5A ), but an inverse agonist at rH 3 R (Fig. 5B) . The type of G protein subunit did not change the pharmacological profile of imoproxifan (Table 3 ). The inverse agonists ciproxifan (8) and thioperamide (10) were more potent but less efficacious at rH 3 R than at hH 3 R and again, the G protein subtype caused no changes in their profiles. Clobenpropit (9) was neither speciesspecific nor did the G protein subtype change its pharmacology. Moreover, there is also a strong linear correlation between potencies and efficacies of imidazole-based ligands at membranes expressing rH 3 R and different Gα i/o -subunits, as was found for the hH 3 R ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 Table 3 ). Thus, the pharmacological profile of the rH 3 R is also very similar under the various experimental conditions and, like at hH 3 R, ligand-specific receptor conformations leading to coupling differences do not exist for the compounds investigated [23] .
Collectively, these results confirm the findings regarding the relative stimulatory and inhibitory effects of histamine and thioperamide, respectively (Table 2) , based on total ligandregulated GTPase activity and are indicative for similar constitutive activity of hH 3 R and rH 3 R under all experimental conditions. If there had been differences in constitutive activity between hH 3 R and rH 3 R, then systematic changes in the potencies of full agonists as well as potencies and efficacies of partial agonists and inverse agonists would have occurred. This, however, was not the case. In contrast, the behaviour of ligands, e. g. impentamine or imoproxifan, at one H 3 R species homolog often opposed each other, against every expectation. Thus, these ligand effects are solely species-specific and not due to differences in constitutive activity of hH 3 R and rH 3 R.
[ 3 H]NAMH binding studies at hH 3 R and rH 3 R.
Since the type of G protein co-expressed did not change the pharmacology of ligands at both hH 3 R and rH 3 R in the steady-state GTPase assay, we performed radioligand binding experiments for a further characterization only at membranes expressing hH 3 R or rH 3 R plus Gα i2 plus β 1 γ 2 dimers.
At first, we addressed the formation of a high-affinity ternary complex between the agonist [ 
13
In competition binding experiments (Fig. 4 C) , histamine (1) (Fig. 5 E and F (4) and proxifan (5) had essentially the same affinities at hH 3 R and rH 3 R. Impentamine (6), imoproxifan (7) (Table 4 ) and steady-state GTPase assays (Table 3) , compared with the literature, were very similar [31, 32] . The pK i and pEC 50 values determined at hH 3 R correlated well, suggesting a direct signal transfer in the Sf9 cell system (Fig. 7) . However, at rH 3 R, the correlation coefficient was rather low, due to an extraordinary high affinity of impentamine (6) . Interestingly, the pK i values of imoproxifan (7) were significantly lower than the corresponding pEC 50 values determined in the GTPase assay (t test, p < 0.05).
Binding mode of imoproxifan at hH 3 R and rH 3 R.
To understand the molecular basis for the unique behaviour of imoproxifan, we performed molecular modelling studies with hH 3 R and rH 3 R. The binding modes of imoproxifan at active hH 3 R and inactive rH 3 R, representing the most favoured ligand-receptor-complexes, are presented in Fig. 8 .
Imoproxifan is bound to hH 3 R and rH 3 R in E-configuration, representing the transisomer of the oxime-moiety. The E-configuration was also determined to be the favoured one by crystallographic studies [33] . The electrostatic surface potential of the amino acids with the ligand in the binding pocket is shown (Fig. 8, A and B) . In hH 3 R and rH 3 R, the positively charged terminal imidazole moiety of imoproxifan interacts with the highly conserved Asp 3.32 ( Fig. 8, A and B, black arrow) . However, there are large differences in electrostatic surface between TM V and TM III (Fig. 8, A and B, yellow, dotted line) . In this region, the electrostatic surface potential is positive in hH 3 R due to the NH moiety of Trp 6.48 , The analoguous region in rH 3 R shows a slightly negative potential due to the OH moiety of Thr 6.52 . The consequence is a different orientation, and thus a different hydrogen bond networking of the oxime moiety 9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 of imoproxifan. In hH 3 R, the methyl moiety points into direction of TM V, whereas in rH 3 R, the methyl moiety points downward.
The reason for the differences in electrostatic surface potential between hH 3 R and rH 3 R are explained by the amino acid difference at position 3.37 between hH 3 R and rH 3 R. In hH 3 R, Glu 5.46 can electrostatically interact with Thr 3.37 ( Fig. 8, C A second species-difference between hH 3 R and rH 3 R near to the binding pocket is located at position 3.40. There is an alanine in hH 3 R, but a bulkier valine in rH 3 R (Fig. 8, C and D, green, dotted line). It is likely that this amino acid difference also directs the oxime moiety of imoproxifan into a distinct orientation. Since Ala 3.40 is not as bulky as Val 3.40 , there is more space for the oxime moiety to point downward in direction to 3.40 in hH 3 R, than in rH 3 R.
Additionally, Trp 6.48 is shown in its active conformation at hH 3 R (Fig. 8, C , blue arrow) and in its inactive conformation in rH 3 R (Fig. 8, D In contrast to imoproxifan (7), ciproxifan (8) (Fig. 4B ) was found to act as an inverse agonist at hH 3 R as well as at rH 3 R. This observation is quite interesting, since both compounds only differ in the substitution pattern at the phenyl moiety (Fig. 2) . To obtain more insight into these pharmacological differences, we docked ciproxifan (8) into the binding pocket of the active conformation of hH 3 R and performed a minimization with regard to potential energy. An overlay with the corresponding imoproxifan -hH 3 R -complex showed, that the cyclopropyl moiety of ciproxifan (8), which is more space-filling than the methyl moiety of imoproxifan (7), lead to a shift of the neighbouring Glu 5.46 away from the binding pocket. Subsequently, the hydrogen bond between Glu 5.46 and Thr 3.37 is broken, which may lead to a destabilization of the entire ligand-receptor complex. In contrast, ciproxifan (8) could be docked very well into the binding pocket of the inactive hH 3 R. The resulting binding mode is similar to that of imoproxifan (7) at the inactive rH 3 R. Since there is the smaller alanine in position 3.40 at hH 3 R (compared to valine at rH 3 R), the more space-filling cycloproyl moiety fits optimally into this small pocket at hH 3 R. However, the exchange of the oxime moiety into a carbonyl moiety in ciproxifan (8) leads to the loss of one hydrogen bond between ligand and receptor, as found for imoproxifan (Fig. 8F ).
DISCUSSION
Ligand pharmacology at hH 3 R and rH 3 R is species-dependent (Fig. 4) [35, 36] .
Unexpectedly, the species-differences can even span from agonism to inverse agonism in the case of imoproxifan [36] . In this study, we unraveled the underlying molecular expressed at similar levels and defined receptor-to-G protein stoichiometries. The basal activity in the two systems was comparable, as indicated by the similar inhibitory effects of the standard inverse agonist thioperamide. Thus, the unexpected behaviour of imoproxifan can only be due to species-specific differences in ligand recognition and receptor activation.
Previous modelling studies described the binding mode of FUB181, a compound, similar to imoproxifan [21] . The orientation of imoproxifan in the binding pocket of H 3 R, determined in the present study, is similar to these previous findings. In another study, it was suggested, that the Ala 3.40 Val amino acid difference between hH 3 R and rH 3 R is responsible for the observed species-differences in antagonist pharmacology [13] . in its inactive conformation due to a hydrophobic interaction. Thus, the modelling studies provide an explanation for the inverse agonism of imoproxifan at rH 3 R on a molecular level, too. Additionally, the molecular modelling studies could be used to explain the switch from partial agonism of imoproxifan (7) to inverse agonism of ciproxifan (8) at hH 3 R. The modelling studies suggest that the main reason for this is the more space-filling cycloproyl moiety of ciproxifan (8), compared to the methyl moiety in imoproxifan (7) . This leads to a loss of hydrogen bonding between Glu 5.46 and Thr 3.37 . Furthermore, a hydrogen bond between the carbonyl moiety and the NH moiety of Trp 6.48 , stabilizing the active conformation of hH 3 R, could not be established.
Interestingly, the pK i values imoproxifan (7) (7) leads to an activation of G proteins, whereas in rH 3 R, the low affinity state inhibited the activation of G proteins.
The G protein coupling profile of hH 3 R and rH 3 R was similar, too (Table 2 ; in [23] ). An important fact is that like for hH 3 R [23] , at rH 3 R no evidence for functional selectivity was observed (Table 3) . However, in another study, evidence for functional selectivity at H 3 R could be obtained [38] . Possible reasons for those discrepancies were already previously discussed [23] . Both hH 3 R and rH 3 R coupled effectively with G i /G o -proteins in Sf9 cell membranes, as was shown by GTPγS-insensitive ternary complex formation, using In line with the data for hH 3 R and rH 3 R, high-affinity agonist binding to the structurally closely related histamine H 4 -receptor is also largely GTPS-insensitive [39] . The H 4 -receptor possesses very high constitutive activity as well. Similar constitutive activity renders the system well suited for the analysis of species-specific ligand effects, since differences in constitutive activity between GPCRs can alter their pharmacological profiles and lead to a further complication of data interpretation [40, 41] .
The pharmacology of all histamine receptors (H x Rs) is species-dependent. This is especially true for H x R agonists. At the H 1 R, several classes of bulky ligands exhibit species differences [42] . Some of them show unique behaviours, like epimeric members of the ergoline family or chiral histaprodifens, switching from silent antagonism to partial agonism depending on the species studied [28, 43] . Detailed molecular studies dissected some of the underlying mechanisms [26, 44] . At the H 2 R, bulky agonists like the long-chained impromidine-and arpromidine-derived guanidines or N G -acylated imidazolylpropylguanidines (AIPGs), are more potent and efficacious at the gpH 2 R than at the hH 2 R [37, 45] . Metiamide was identified to be an inverse agonist at the hH 2 R, gpH 2 R and rH 2 R, but a weak partial agonist at the cH 2 R [40] . At the H 4 R, which has the lowest sequence similarity between species, studies focusing on ligand-receptor interactions of agonists are beginning to emerge [27, 46] . However, the species-differences of imoproxifan at hH 3 R and rH 3 R described in this study represent the most substantial differences in pharmacology among H X Rs identified so far. This is particularly compelling in view of the fact that hH 3 R and rH 3 R sequences display a high degree of homology and only two amino acid residues cause the disparities.
In conclusion, we have shown that hH 3 R and rH 3 R expressed in Sf9 cells both similarly couple to defined G i /G o -protein heterotrimers and display similar constitutive activities. We show species-differences in pharmacological properties of imoproxifan and offer an explanation on the molecular basis for these differences. Most importantly, we introduce novel active state models of hH 3 R and rH 3 R, that are suitable to explain the efficacy of H 3 R ligands.
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TABLES
[³H]JNJ-7753707 saturation bindings were performed as described under Methods. A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 65 A c c e p t e d M a n u s c r i p t , and the maximal stimulatory effect of histamine (10 µM) amounted to ~40
to ~90% above basal. The efficacy (E max ) of histamine was determined by nonlinear regression and was set to 1.00. The E max values of other agonists and inverse agonists were referred to this value. Data shown are the means ± S. E. M. of three to four experiments performed in duplicates each. Statistical analysis was performed using one-way ANOVA, followed by Dunnet's multiple comparison test using the values determined at hH 3 R, Gα i2 and β 1 γ 2 as a reference. Significant differences to the membrane expressing Gα i2 are shown following comparison with other Gα i/o subunits. (no symbol: not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001). Additionally, data shown were correlated and analyzed by linear regression. The potencies and efficacies of ligands at membranes co-expressing the rH 3 R, Gα i1 , Gα i3 or Gα o1 , and β 1 γ 2 dimers, respectively, were correlated with values determined at the reference membrane expressing Gα i2 . The correlation coefficients (r 2 ) and the slopes are presented at the bottom of the table. a n u s c r i p t 
